http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103058914-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2012-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103058914-B |
| titleOfInvention | Maleic acid levorotation amlodipine crystal form and preparation method thereof |
| abstract | Crystal formation that the invention discloses Levoamlodipine Maleate and preparation method thereof, Maleic acid levorotation amlodipine crystal form X-ray diffraction of the present invention at 2 θ is: there is peak at 13.1 ± 0.2 °, 13.5 ± 0.2 °, 15.6 ± 0.2 °, 17.5 ± 0.2 °, 22.5 ± 0.2 °, 23.1 ± 0.2 °, 26.4 ± 0.2 °, 29.0 ± 0.2 °, 30.2 ± 0.2 °, 35.3 ± 0.2 ° places.Maleic acid levorotation amlodipine crystal form content (or purity) of the present invention is high, foreign matter content is low, steady quality, for the clinical application of Levoamlodipine Maleate medicine provides safety control. |
| priorityDate | 2012-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.